Based on previously unpublished data, IQWiG concludes that lecanemab offers no proven benefit over the current standard of care in Germany. Our assessment is based on previously unpublished data which the manufacturer was required to provide in its dossier. Thanks to the high level of transparency in the German AMNOG procedure, these are now also available to the public. Lecanemab has been available in Germany for the treatment of early-stage Alzheimer’s disease since September 2025. The drug is intended to slow the progression of the disease and must only be used in adults who The German Institute for Quality and Efficiency in Health Care(IQWiG) has now examined in a benefit assessment whether lecanemab offers benefits over the present
IQWiG (German HTA) · December 01, 2025
Lecanemab for early-stage Alzheimer's disease: IQWiG benefit assessment concludes no added benefit
Original title: Lecanemab for early-stage Alzheimer’s disease: Previously unpublished data show no added benefit
IQWiG's benefit assessment of lecanemab for early-stage Alzheimer's disease, based on previously unpublished manufacturer data, finds no proven added benefit over current standard care.
Published by IQWiG (German HTA). HealthSignal links to the original document; the summary above is extracted from the source text.